Strut Health review: what the FDA warning letter, and the site itself, say
On 20 February 2026 the FDA told Strut to stop marketing compounded tirzepatide as a generic of Zepbound and Mounjaro. On 6 September 2026 that wording was gone from the site, but the letter's other finding — that Strut's own name on the label implies it compounds drugs it does not — was not fixed: the partner pharmacy was still unnamed.
In February 2026 the FDA sent Strut Health a warning letter. By 6 September the wording the agency quoted was gone from the tirzepatide page we checked. The finding underneath it has not been addressed at all, and it is the one that matters more: Strut does not tell you which pharmacy makes your medication.
What Strut Health is
Strut Health, LLC, trading as Strut, operates from 701 Commerce Street in Dallas. Medical services are delivered through a separate professional entity, Titan Health, P.A. The founder and chief executive is Dr. Simal Patel, and the company describes itself as "a Partex.AI Consumer Health Company." The domain was registered in December 2018.
The menu is wider than a weight-loss brand's. Their own navigation splits it eight ways: hair loss, sexual health, skin care, weight loss, health testing, sleep, wellness and longevity, and — on the women's side — menopause. Compounded semaglutide and tirzepatide sit alongside sildenafil, tadalafil, finasteride, tretinoin blends, sermorelin, enclomiphene and injectable NAD+.
The clinical model is asynchronous. You complete a medical questionnaire, a physician reviews it, and in most states a prescription follows without a live visit.
The warning letter, read in full
We read the letter at fda.gov on 6 September 2026.
It is dated 20 February 2026, posted 3 March 2026, MARCS-CMS 721448, from the Center for Drug Evaluation and Research, addressed to Simal Patel, MD as chief executive, and signed by the acting director of CDER's Office of Compounding Quality and Compliance. FDA states it reviewed struthealth.com in December 2025.
Two findings. The first is the labelling: the compounded semaglutide and tirzepatide products pictured on the site "identify 'Strut' on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not."
The second is three statements FDA quoted from the site, verbatim: "Generic Zepbound, Mounjaro"; "Semaglutide is the active ingredient in the brand medications."; and "Tirzepatide is the active ingredient in the brand medications Zepbound® and Mounjaro®." Compounded drugs are not FDA-approved, and claims that imply otherwise make the product misbranded.
FDA cited sections 502(a), 502(bb), 301(a) and 301(c) of the Federal Food, Drug and Cosmetic Act, gave fifteen working days to respond, and named seizure and injunction as the consequences of not doing so.
Strut was not singled out. Two other letters went out the same day, were posted the same day, came from the same office and carry the same subject line: Lean Rx, Inc. dba SkinnyRx and Newman Clinic, PLLC. Three companies, one action, one subject line: "False & Misleading Claims/Misbranded (Telehealth)".
What changed on the site, and what did not
We pulled the injectable tirzepatide page on 6 September 2026. The wording FDA quoted is not on it. In the footnote instead: "Compounded medications are not FDA-approved and have not gone through FDA safety and efficacy review." The letter demanded the claims come down rather than dictating replacement wording. On this page they are down; we did not audit every page on the site, and we cannot say when the change was made.
The labelling finding is harder to close, and it has not been. No pharmacy is named — not on the product pages, not in the FAQ, not in the terms, not in the refund policy. Their telemedicine consent says prescriptions go "to the pharmacy of your choice or to Strut Health's partner pharmacy", which is a real option and worth knowing: you can route the script to a pharmacy you are able to check. Take the default and you cannot. Meanwhile the homepage carries "PCAB Accredited" and "ACHC Accredited Compounding Pharmacy" badges — accreditations a compounding pharmacy earns, not a telehealth platform — while the pharmacy that earns them goes unnamed.
The database shows the letter posted with no closure record attached. That is all it shows: a response may have been accepted and not published, or the file may be open. What is checkable is the public record, and on the public record this matter is not closed.
The regulatory ground underneath
Compounded semaglutide and tirzepatide were lawful at scale because both were on the FDA shortage list. Tirzepatide came off on 2 October 2024; the Outsourcing Facilities Association sued, and the FDA re-declared the shortage resolved on 19 December 2024, which is the determination the enforcement clock ran from. Semaglutide came off in February 2025. The wind-down deadlines were 18 February and 19 March 2025 for tirzepatide, 22 April and 22 May 2025 for semaglutide.
A district court denied the OFA's preliminary injunction on 5 March 2025 and upheld the FDA on the merits on 7 May 2025. On 30 April 2026 the agency went further and proposed excluding semaglutide, tirzepatide and liraglutide from the 503B Bulks List permanently.
What survives is narrow: patient-specific compounding under 503A, where a clinician documents that the approved drug will not do for this particular patient. Strut's own product page states the gate in those terms — compounded tirzepatide is "only available for patients that fail or cannot use other commercially available GLP-1 receptor agonist medications," with medical necessity required. That is the correct standard, printed on the page. Whether an asynchronous questionnaire establishes it for each patient is a different question, and not one the site answers.
The prices, which used to disagree
Injectable semaglutide is $129 a month on auto-refill, the page spelling out "Save 13% with auto-refill". On 6 September 2026 it was not the only figure: the men's product page and the women's weight-loss page then charged $149 for the same drug, with the same 13% saving, while this page showed $129. The Internet Archive holds the men's page at $149 on 10 October. By 9 November that address redirected to the $129 page.
In September the women's weight-loss page also quoted its four products in two different units: injectable semaglutide at $149 and oral semaglutide at $99, against injectable tirzepatide at $4.97 a day and oral tirzepatide at $6.63 a day, under a heading that read "TRANSPARENT PRICING." The weight-loss page no longer lists prices. On 9 November the product pages all led with a monthly figure: oral semaglutide $99, injectable tirzepatide from $149 and oral tirzepatide from $199, the last still also shown as $6.63 a day.
Every price is an auto-refill rate carrying a "Save X%" badge. The undiscounted price those percentages are calculated from is not published anywhere we could find.
Clinical process, as described
The intake is a questionnaire, submitted asynchronously. Ongoing care is described as physician messaging through the patient portal, with dose adjustments handled the same way. At-home lab panels are sold as an add-on, not required before prescribing.
That is what the site says about itself. We did not create an account, complete an intake or receive a prescription.
Consumer signals
Trustpilot shows a profile claimed in July 2026 with no reviews on it and a score of 0.0. That is an absence, not a verdict.
One thing we can confirm ourselves. Their FAQ says: "As of September 2024, we can ship to all states except for Arkansas." The stamp is two years old and still on the page.
Who it may suit
Someone who knows which compounded product they want, is not in Arkansas, accepts that the compounding pharmacy will not be named, and reads the headline price as a starting point. The asynchronous model is lawful in most states and Strut is unremarkable in using it. The eight-category menu is a real convenience if you want a hair-loss and a weight-loss prescription from one account.
Who should look elsewhere
Anyone who wants to know which pharmacy compounds their injectable before paying. That is not on the site, and it is the exact point the FDA raised.
Anyone who wants one price for one product. Two live figures for injectable semaglutide is not a rounding difference.
Anyone in Arkansas.
Anyone who wants a closed FDA file. The public record doesn't show one.
Editorial verdict
Strut deleted the words the FDA quoted. That was the minimum the letter required, and by September the page we checked was clean.
The finding underneath is untouched. Accreditation badges belonging to a pharmacy, product labels carrying the Strut name, and a consent form that says "partner pharmacy" — all still on the site, and a patient reading carefully still cannot tell who made their injection. Around it sit the two live semaglutide prices, the two-year-old shipping notice, and an empty Trustpilot profile. Each is minor. Together they describe a site nobody is maintaining as though the small print counted.
The compounded GLP-1 market is not getting looser. The operators still standing in 2027 will be the ones who name their pharmacy, publish one price per product, keep their notices current, and get their regulatory files closed on the public record. Strut has done none of those four. It has done the one thing the letter compelled.
Who makes the medication
From Strut Health’s public pages, read Sep 24, 2026.
| Pharmacy | Not named on its public pages |
| Prescriber | Names a medical group, no clinicians: Titan Medical Group |
Its telemedicine consent says prescriptions go "to the pharmacy of your choice or to Strut Health's partner pharmacy", and the partner is not named. The consent names the medical group; the FAQ describes "U.S.-licensed and board-certified physicians" without names.
Read from: Strut Health telemedicine consent, Strut Health FAQ.
How the other providers we cover answer the same question: which telehealth providers name their pharmacy.
Frequently asked
What did the FDA warning letter actually say?
Two things. That the product labels pictured on the site "identify 'Strut' on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not." And that three quoted statements — including "Generic Zepbound, Mounjaro" — made the compounded products misbranded. The letter is dated 20 February 2026 and was posted 3 March 2026.
Has Strut fixed it?
Partly. The wording the FDA quoted is gone from the tirzepatide page we checked on 6 September 2026. The labelling finding is not addressed: no pharmacy is named on the product pages, in the FAQ, in the terms or in the refund policy. The warning-letter database shows no closure record attached.
Which pharmacy makes my medication?
Strut doesn't say. The telemedicine consent does give you an option worth using: prescriptions go "to the pharmacy of your choice or to Strut Health's partner pharmacy". Choose your own and you can check it. Take the default and you can't.
Why does the homepage show pharmacy accreditations?
It carries "PCAB Accredited" and "ACHC Accredited Compounding Pharmacy" badges. Those are accreditations a compounding pharmacy earns, not a telehealth platform — and the pharmacy that earned them is not named.
What does injectable semaglutide cost?
$129 a month on auto-refill, read on 9 November 2026. On 6 September two answers were live at once — $149 on the men's page and the women's weight-loss page, $129 on a third page — and the men's page still showed $149 on 10 October; it now redirects to the $129 page. Prices are auto-refill rates carrying a "Save X%" badge, and on the injectable semaglutide page the undiscounted price that percentage comes from is not published.
Can Strut ship to my state?
The FAQ says: "As of September 2024, we can ship to all states except for Arkansas." That stamp is two years old and still on the page.
Do I need a live appointment?
No. The model is asynchronous — a questionnaire, a physician review, and in most states a prescription without a live visit. At-home lab panels are sold as an add-on, not required before prescribing.
Editorial note: This page is for informational purposes and doesn't constitute medical advice. Peptide therapy and GLP-1 prescribing decisions should be made with a licensed healthcare provider familiar with your medical history. Regulatory status of compounded semaglutide and tirzepatide is dynamic; verify current FDA guidance before making treatment decisions.
Prices
What Strut Health charges, and how you start
This review is about whether the company holds up, so it carries no price list — a figure printed here would be stale within a month and would turn an assessment into a storefront. PeptidesToGo keeps the pricing, read from Strut Health’s own pages and dated.
See Strut Health’s plans and pricingPeptides To Go · plans, entry price and what the bill excludes